



an Open Access Journal by MDPI

## Nanoparticle-Based Drug Targeting for the Treatment of Cardiovascular Disorders

Guest Editors:

**Dr. Eliana Hiromi Akamine**

Departamento de Farmacologia,  
Instituto de Ciências Biomédicas,  
Universidade de São Paulo, São  
Paulo, Brazil

**Dr. Stephen Fernandes  
Rodrigues**

Departamento de Farmacologia,  
Instituto de Ciências Biomédicas,  
Universidade de São Paulo, São  
Paulo, Brazil

Deadline for manuscript  
submissions:  
**closed (30 April 2023)**

### Message from the Guest Editors

Cardiovascular diseases represent a group of heart and circulatory disease conditions, which include coronary heart disease, subclinical atherosclerosis, heart failure, stroke, rhythm disorders, venous disease, peripheral vascular disease, and various other conditions. Nanoparticles have already been marketed to treat a few diseases, such as some forms of cancer, and they are soon set to be approved for use in the treatment of other conditions, such as cardiovascular disease. This Special Issue invites the submission of manuscripts that address nanoparticle-based drug targeting for the treatment of cardiovascular diseases. Potential topics include, but are not limited to, the reduction in or prevention of atherosclerotic lesions, thrombi formation, and vascular inflammation and dysfunction. Manuscripts that address reductions in cardiovascular risk factors (cholesterol, blood pressure and glucose control) are also welcome. Original research and review articles are requested that describe innovative nanoparticle- and nanocarrier-based drug delivery, the new use of known nanoparticles, and mechanisms of action underlying the cardiovascular effects of the nanoparticles



[mdpi.com/si/119795](https://mdpi.com/si/119795)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)